Development and validation of prognostic nomograms for metastatic gastrointestinal stromal tumour treated with imatinib

Chee Khoon Lee; David Goldstein; Emma Gibbs; Heikki Joensuu; John Zalcberg; Jaap Verweij; Paolo G. Casali; Robert G. Maki; Angela Cioffi; Grant A. McArthur; Sarah J. Lord; Desmond Yip; Yada Kanjanapan; Piotr Rutkowski

doi:10.1016/j.ejca.2015.02.015

JOURNAL ARTICLE

Development and validation of prognostic nomograms for metastatic gastrointestinal stromal tumour treated with imatinib

Chee Khoon Lee David Goldstein Emma Gibbs Heikki Joensuu John Zalcberg Jaap Verweij Paolo G. Casali Robert G. Maki Angela Cioffi Grant A. McArthur Sarah J. Lord Desmond Yip Yada Kanjanapan Piotr Rutkowski

Year: 2015 Journal: European Journal of Cancer Vol: 51 (7)Pages: 852-860 Publisher: Elsevier BV

DOI: 10.1016/j.ejca.2015.02.015

Get Full-Text PDF Get Analytical Report

Keywords:

Nomogram Medicine Internal medicine GiST Hazard ratio Imatinib Oncology Proportional hazards model Confidence interval Cohort Framingham Risk Score Stromal cell Disease

Metrics

Cited By

3.75

FWCI (Field Weighted Citation Impact)

Refs

0.92

Citation Normalized Percentile

Is in top 1%

Is in top 10%

Citation History

Topics

Gastrointestinal Tumor Research and Treatment

Health Sciences → Medicine → Gastroenterology

Neurofibromatosis and Schwannoma Cases

Health Sciences → Medicine → Neurology

Soft tissue tumor case studies

Health Sciences → Medicine → Rheumatology

Development and validation of prognostic nomograms for metastatic gastrointestinal stromal tumour treated with imatinib

Metrics

Citation History

Topics

Related Documents

Gastrointestinal stromal tumour treated with neoadjuvant imatinib

Clinical prognostic factors in metastatic gastrointestinal stromal tumors (GIST) patients treated with Imatinib

Tumour Lysis Syndrome Occurring in a Patient with Metastatic Gastrointestinal Stromal Tumour Treated with Glivec (Imatinib Mesylate, Gleevec, STI571)

Complete Remission With Imatinib in Metastatic Gastrointestinal Stromal Tumors

Clinical implications of repeated drug monitoring of imatinib in patients with metastatic gastrointestinal stromal tumour